TY - JOUR
T1 - Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes
T2 - The Diabetes Outcomes in Veterans Study (DOVES)
AU - Murata, Glen H.
AU - Hoffman, Richard M.
AU - Duckworth, William C.
AU - Wendel, Christopher S.
AU - Shah, Jayendra H.
N1 - Funding Information:
Supported by a grant (VCR 99–007) from the Health Services Research & Development Service and the Veterans Integrated Service Network 18, Department of Veterans Affairs.
PY - 2004/6
Y1 - 2004/6
N2 - Background: Daily self-monitored blood glucose testing is recommended for patients with insulin-treated type 2 diabetes. However, most patients do not test frequently enough for optimal glycemic control. Less frequent testing may be sufficient for assessing glycemic control among stable patients as well as improving patient compliance. The study objective was to evaluate the weekly contribution of glucose readings to hemoglobin (Hb)A1c during an 8-week period of intensified self-monitored blood glucose testing. Methods: The authors randomly selected stable, insulin-treated subjects with type 2 diabetes. Subjects monitored their blood glucose four times daily for 8 weeks; the authors then downloaded glucose meters and measured an HbA1c. Mean blood glucose values were calculated for each of the 8 weeks. Multiple linear regression analyses examined the contribution of these mean values to the HbA1c. Results: A total of 182 subjects completed the monitoring protocol; mean HbA1c was 7.63 ± 1.42%, mean glucose was 9.78 ± 2.27 mmol/L, the regression correlation was 0.77, P < 0.001. A fitted multiple linear model using all 8 weekly mean blood glucose values showed large variation in their independent contributions to the HbA1c. Mean blood glucose values from consecutive weeks were highly correlated and did not provide independent information about glycemic control. Stepwise regression showed that the mean blood glucose values from weeks 4, 6, and 8 significantly and equally influenced HbA1c. Conclusions: Glycemic control can be efficiently assessed by reviewing at least 5 weeks' worth of monitoring results, focusing on alternate weeks and giving less weight to more remote readings.
AB - Background: Daily self-monitored blood glucose testing is recommended for patients with insulin-treated type 2 diabetes. However, most patients do not test frequently enough for optimal glycemic control. Less frequent testing may be sufficient for assessing glycemic control among stable patients as well as improving patient compliance. The study objective was to evaluate the weekly contribution of glucose readings to hemoglobin (Hb)A1c during an 8-week period of intensified self-monitored blood glucose testing. Methods: The authors randomly selected stable, insulin-treated subjects with type 2 diabetes. Subjects monitored their blood glucose four times daily for 8 weeks; the authors then downloaded glucose meters and measured an HbA1c. Mean blood glucose values were calculated for each of the 8 weeks. Multiple linear regression analyses examined the contribution of these mean values to the HbA1c. Results: A total of 182 subjects completed the monitoring protocol; mean HbA1c was 7.63 ± 1.42%, mean glucose was 9.78 ± 2.27 mmol/L, the regression correlation was 0.77, P < 0.001. A fitted multiple linear model using all 8 weekly mean blood glucose values showed large variation in their independent contributions to the HbA1c. Mean blood glucose values from consecutive weeks were highly correlated and did not provide independent information about glycemic control. Stepwise regression showed that the mean blood glucose values from weeks 4, 6, and 8 significantly and equally influenced HbA1c. Conclusions: Glycemic control can be efficiently assessed by reviewing at least 5 weeks' worth of monitoring results, focusing on alternate weeks and giving less weight to more remote readings.
KW - Hemoglobin A1c
KW - Multivariate regression analyses
KW - Non-insulin-dependent diabetes mellitus
KW - Self-monitored blood glucose
UR - http://www.scopus.com/inward/record.url?scp=2942644951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942644951&partnerID=8YFLogxK
U2 - 10.1097/00000441-200406000-00004
DO - 10.1097/00000441-200406000-00004
M3 - Article
C2 - 15201644
AN - SCOPUS:2942644951
SN - 0002-9629
VL - 327
SP - 319
EP - 323
JO - American Journal of the Medical Sciences
JF - American Journal of the Medical Sciences
IS - 6
ER -